CINCINNATI, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT) (TSXV: QIPT), a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced that it will host its Fiscal Q1 2023 earnings conference call and audio webcast on Tuesday, February 14, 2023 at 10:00 a.m. (EST).
Conference Call Details:
Tuesday, February 14, 2023 at 10:00 a.m. (EST).
| Canada/US Toll Free: | 1 (800) 319 4610 |
| International: | 1 (604) 638 5340 |
Audio Webcast Details:
The live audio webcast can be found on the investor section of the Company’s website through the following link: www.quipthomemedical.com
ABOUT QUIPT HOME MEDICAL CORP.
The Company provides in-home monitoring and disease management services including end-to-end respiratory solutions for patients in the United States healthcare market. It seeks to continue to expand its offerings to include the management of several chronic disease states focusing on patients with heart or pulmonary disease, sleep disorders, reduced mobility, and other chronic health conditions. The primary business objective of the Company is to create shareholder value by offering a broader range of services to patients in need of in-home monitoring and chronic disease management. The Company’s organic growth strategy is to increase annual revenue per patient by offering multiple services to the same patient, consolidating the patient’s services, and making life easier for the patient.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information please visit our website at www.quipthomemedical.com, or contact:
Cole Stevens
VP of Corporate Development
Quipt Home Medical Corp.
859-300-6455
This email address is being protected from spambots. You need JavaScript enabled to view it.
Gregory Crawford
Chief Executive Officer
Quipt Home Medical Corp.
859-300-6455
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.42 |
| Daily Change: | -0.03 -1.22 |
| Daily Volume: | 173,600 |
| Market Cap: | US$104.280M |
December 18, 2023 September 11, 2023 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
